Detailed Narrative
Strong Q3 FY25 Performance and Upgraded Guidance
Ami Organics reported robust Q3 FY25 results, with revenue from operations growing 65.2% YoY and 11.5% QoQ to INR 275 crores. Gross profit increased by 78% YoY to INR 127.2 crores, leading to a gross margin of 46.2%, an expansion of 333 bps YoY. EBITDA surged over 2.5x YoY to INR 68.7 crores, with the EBITDA margin reaching 25%, up 904 bps YoY. Consequently, the company revised its FY25 revenue growth guidance upward from 30% to 35%.
CDMO Business as a Key Growth Driver
The CDMO business is identified as a significant growth engine, with management anticipating it to reach approximately INR 1,000 crores by FY28, a substantial increase from INR 80-90 crores in FY24. The company is actively progressing several additional CDMO projects, with many expected to commercialize by FY26. This growth is supported by new facilities at Ankleshwar, where Block 2 has commercialized and Block 1 is expected to commercialize by the end of Q3 FY25.
Strategic Focus on Chemistry and Diversification
Ami Organics emphasizes its core strength in chemistry, which drives its business model across originator, generic, and first-to-file segments, providing business security until 2040. The company maintains a diversified approach across Pharma, Agro, Specialty, Polymer, and Petrochemicals to mitigate risks from single-segment dependence. This strategy ensures stability and continuous growth, even when one segment faces challenges, as evidenced by consistent revenue improvement.
Investments in New Growth Avenues
The company is building new growth engines in semiconductor chemicals and electrolyte additives. In semiconductor chemicals, Ami Organics is developing photoresist chemicals and other backend packaging chemicals, with samples being sent to Japan and Korea for maturation in the coming years. For electrolyte additives, CAPEX of INR 170 crores is underway, with completion expected by H1 FY26, and the company is strategically positioning itself with long-term contracts and competitive pricing.
Capacity Utilization and Expansion
Current capacity utilization at Unit-1 Sachin is over 70%, while Unit-2 (Block 3) and Unit-3 are at 50%. The company has sufficient room for Pharma Intermediate business for the next 2-3 years. The commercialization of Block 1 at Unit-2 by the end of Q3 FY25 will further enhance capacity. Additionally, an 8,000 square meter land parcel is available at Sachin GIDC for future high CAPEX requirements.
Working Capital Management and Liquidity
Despite strong growth, Ami Organics effectively managed its working capital, reducing it from 108 days in H1 FY25 to 95 days in 9M FY25. This efficient management contributed to strong cash flow from operations of INR 119 crores, representing 81% of EBITDA for the nine-month period. The company maintains a healthy liquidity position with net cash and cash equivalents of INR 306 crores.